Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma

Oncogene

Volumn 35, Issue 26, 2016, Pages 3432-3442

  Semprucci, E ^a   Tocci, P ^a   Cianfrocca, R ^a   Sestito, R ^a   Caprara, V ^a   Veglione, M ^a   Di Castro, V ^a   Spadaro, F ^b   Ferrandina, G ^c   Bagnato, A ^a   Rosano L ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN 1; ENDOTHELIN A RECEPTOR; MACITENTAN; MATRIX METALLOPROTEINASE 14; PDZ PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR; ACTIN; ACTIN DEPOLYMERIZING FACTOR; ARHGEF11 PROTEIN, HUMAN; BETA ARRESTIN; CORTACTIN; LIM KINASE; LIMK1 PROTEIN, HUMAN; RHO KINASE; RHOC PROTEIN, HUMAN; SH3PXD2A PROTEIN, HUMAN; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; COMPARATIVE STUDY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PODOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; ANIMAL; CELL MOTION; GENETICS; IMMUNOBLOTTING; METABOLISM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ACTIN DEPOLYMERIZING FACTORS; ACTINS; ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; BETA-ARRESTINS; CELL LINE, TUMOR; CELL MOVEMENT; CORTACTIN; FEMALE; HUMANS; IMMUNOBLOTTING; LIM KINASES; MATRIX METALLOPROTEINASE 14; MICE, NUDE; OVARIAN NEOPLASMS; PODOSOMES; RECEPTOR, ENDOTHELIN A; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO GTP-BINDING PROTEINS; RHO GUANINE NUCLEOTIDE EXCHANGE FACTORS; RHO-ASSOCIATED KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84976904251     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.403     Document Type: Article

References (58)

1. Hall A. The cytoskeleton and cancer. Cancer Metast Rev 2009; 28: 5-14.
2. Sahai E, Marshall CJ. Rho-GTPases and cancer. Nat Rev Cancer 2002; 2: 133-142.
3. Spiering D, Hodgson L. Dynamics of the Rho-family small GTPases in actin regulation and motility. Cell Adhes Migr 2011; 2: 1-11.
4. Siehler S. Regulation of RhoGEF proteins by G12/13-coupled receptors. Br J Pharmacol 2009; 158: 41-49.
5. Fukuhara S, Chikumi H, Galisteo R, Mukouyama YS, Bugge TH, Gutkind JS. PDZRhoGEF and LARG are essential for embryonic development and provide a link between thrombin and LPA receptors and Rho activation. J Biol Chem 2013; 26: 12232-12243.
6. Aittaleb M, Gao G, Evelyn CR, Neubig RR, Tesmer JJ. A conserved hydrophobic surface of the LARG pleckstrin homology domain is critical for RhoA activation in cells. Cell Signal 2009; 21: 1569-1578.
7. Zheng R, Iwase A, Shen R, Goodman Jr OB, Sugimoto N, Takuwa Y et al. Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase. Oncogene 2006; 25: 5942-5952.
8. Murphy DA, Courtneidge SA. The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol 2011; 12: 413-426.
9. Saykali BA, El-Sibai M. Invadopodia, regulation, and assembly in cancer cell invasion. Cell Commun Adhes 2014; 21: 207-212.
10. Ward JD, Ha JH, Jayaraman M, Dhanasekaran DN. LPA-mediated migration of ovarian cancer cells involves translocalization of Gai2 to invadopodia and association with Src and β-pix. Cancer Lett 2015; 356: 382-391.
11. Ridley AJ. RhoA, RhoB and RhoC have different roles in cancer cell migration. J Microsc 2013; 251: 242-249.
12. Bravo-Cordero JJ, Oser M, Chen X, Eddy R, Hodgson L, Condeelis J. A novel spatiotemporal RhoC activation pathway locally regulates cofilin activity at invadopodia. Curr Biol 2011; 21: 635-644.
13. Gligorijevic B, Wyckoff J, Yamaguchi H, Wang Y, Roussos ET, Condeelis J. N-WASPmediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors. J Cell Sci 2012; 125: 724-734.
14. Eckert MA, Lwin TM, Chang AT, Kim J, Danis E, Ohno-Machado L et al. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 2011; 19: 372-386.
15. Moshfegh Y, Bravo-Cordero JJ, Miskolci V, Condeelis J, Hodgson L. A Trio-Rac1-Pak1 signalling axis drives invadopodia disassembly. Nat Cell Biol 2014; 16: 574-586.
16. Roh-Johnson M, Bravo-Cordero JJ, Patsialou A, Sharma VP, Guo P, Liu H et al. Macrophage contact induces RhoA GTPase signaling to trigger tumor cell intravasation. Oncogene 2014; 33: 4203-4212.
17. Pichot CS, Arvanitis C, Hartig SM, Jensen SA, Bechill J, Marzouk S et al. Cdc42-interacting protein 4 promotes breast cancer cell invasion and formation of invadopodia through activation of N-WASp. Cancer Res 2010; 70: 8347-8356.
18. Rosanò L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2013; 13: 637-651.
19. Shukla AK, Xiao K, Lefkowitz RJ. Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci 2011; 36: 457-469.
20. Min J, Defea K. β-Arrestin-dependent actin reorganization: bringing the right players together at the leading edge. Mol Pharmacol 2011; 80: 760-768.
21. DeFea KA. Arrestins in actin reorganization and cell migration. Prog Mol Biol Transl Sci 2013; 118: 205-222.
22. Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 2009; 24: 2806-2811.
23. Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F et al. β-Arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling. Oncogene 2013; 32: 5066-5077.
24. Spinella F, Caprara V, Di Castro V, Rosanò L, Cianfrocca R, Natali PG et al. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells. J Mol Med 2013; 91: 395-405.
25. Rosanò L, Varmi M, Salani D, Di Castro V, Spinella F, Natali PG et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 2001; 61: 8340-8346.
26. Rosanò L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 2005; 65: 11649-11657.
27. Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V et al. Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res 2014; 74: 7453-7464.
28. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T et al. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003; 83: 861-870.
29. Zhao Y, Zong ZH, Xu HM. RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9. Gynecol Oncol 2010; 116: 563-571.
30. Korkina O, Dong Z, Marullo A, Warshaw G, Symons M, Ruggieri R. The MLK-related kinase (MRK) is a novel RhoC effector that mediates lysophosphatidic acid (LPA)-stimulated tumor cell invasion. J Biol Chem 2013; 288: 5364-5373.
31. Zhao Y, Zheng HC, Chen S, Gou WF, Xiao LJ, Niu ZF. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy. Gynecol Oncol 2013; 130: 570-578.
32. Gou WF, Zhao Y, Lu H, Yang XF, Xiu YL, Zhao S et al. The role of RhoC in epithelialto-mesenchymal transition of ovarian carcinoma cells. BMC Cancer 2014; 14: 477.
33. Chen S, Wang J, Gou WF, Xiu YL, Zheng HC, Zong ZH et al. The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma. Int J Mol Sci 2013; 14: 24187-24199.
34. Cook DR, Rossman KL, Der CJ. Rho guanine nucleotide exchange factors: regulators of Rho GTPase activity in development and disease. Oncogene 2014; 33: 4021-4035.
35. Anthony DF, Sin YY, Vadrevu S, Advant N, Day JP, Byrne AM et al. β-Arrestin 1 inhibits the GTPase-activating protein function of ARHGAP21, promoting activation of RhoA following angiotensin II type 1A receptor stimulation. Mol Cell Biol 2011; 31: 1066-1075.
36. Ma X, Zhao Y, Daaka Y, Nie Z. Acute activation of β2-adrenergic receptor regulates focal adhesions through βArrestin2-and p115RhoGEF protein-mediated activation of RhoA. J Biol Chem 2012; 287: 18925-18936.
37. Mythreye K, Blobe GC. The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci USA 2009; 106: 8221-8226.
38. Bhattacharya M, Anborgh PH, Babwah AV, Dale LB, Dobransky T, Benovic JL et al. Beta-arrestins regulate a Ral-GDS Ral effector pathway that mediates cytoskeletal reorganization. Nat Cell Biol 2002; 4: 547-555.
39. Bravo-Cordero JJ, Magalhaes MA, Eddy RJ, Hodgson L, Condeelis J. Functions of cofilin in cell locomotion and invasion. Nat Rev Mol Cell Biol 2013; 14: 405-415.
40. Yamaguchi H, Lorenz M, Kempiak S, Sarmiento C, Coniglio S, Symons M et al. Molecular mechanisms of invadopodium formation: the role of the N-WASPArp2/3 complex pathway and cofilin. J Cell Biol 2005; 168: 441-452.
41. Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011; 17: 2350-2360.
42. Ogata S, Morishige K, Sawada K, Hashimoto K, Mabuchi S, Kawase C et al. Fasudil inhibits lysophosphatidic acid-induced invasiveness of human ovarian cancer cells. Int J Gynecol Cancer 2009; 19: 1473-1480.
43. Cleghorn WM, Branch KM, Kook S, Arnette C, Bulus N et al. Arrestins regulate cell spreading and motility via focal adhesion dynamics. Mol Biol Cell 2015; 26: 622-635.
44. Shankar H, Michal A, Kern RC, Kang DS, Gurevich VV et al. Non-visual arrestins are constitutively associated with the centrosome and regulate centrosome function. J Biol Chem 2010; 285: 8316-8329.
45. Ma X, Espana-Serrano L, Kim WJ, Thayele Purayil H, Nie Z, Daaka Y. β-Arrestin1 regulates the guanine nucleotide exchange factor RasGRF2 expression and the small GTPase Rac-mediated formation of membrane protrusion and cell motility. J Biol Chem 2014; 289: 13638-13650.
46. Mittal N, Roberts K, Pal K, Bentolila LA, Fultz E, Minasyan A et al. Select G-proteincoupled receptors modulate agonist-induced signaling via a ROCK, LIMK, and β-arrestin 1 pathway. Cell Rep 2013; 5: 1010-1021.
47. Zoudilova M, Min J, Richards HL, Carter D, Huang T, DeFea KA. beta-Arrestins scaffold cofilin with chronophin to direct localized actin filament severing and membrane protrusions downstream of protease-activated receptor-2. J Biol Chem 2010; 285: 14318-14329.
48. Xiao K, McClatchy DB, Shukla AK, Zhao Y, Chen M, Shenoy SK et al. Functional specialization of beta-arrestin interactions revealed by proteomic analysis. Proc Natl Acad Sci USA 2007; 104: 12011-12016.
49. Struckhoff AP, Rana MK, Kher SS, Burow ME, Hagan JL, Del Valle L et al. PDZRhoGEF is essential for CXCR4-driven breast tumor cell motility through spatial regulation of RhoA. J Cell Sci 2013; 126: 4514-4526.
50. Patel M, Kawano T, Suzuki N, Hamakubo T, Karginov AV, Kozasa T. Ga13/PDZRhoGEF/ RhoA signaling is essential for gastrin-releasing peptide receptormediated colon cancer cell migration. Mol Pharmacol 2014; 86: 252-262.
51. Dunn HA, Ferguson SS. PDZ protein regulation of GPCR trafficking and signaling pathways. Mol Pharmacol 2015; 88: 624-639.
52. Martín-Villar E, Borda-d'Agua B, Carrasco-Ramirez P, Renart J, Parsons M, Quintanilla M et al. Podoplanin mediates ECM degradation by squamous carcinoma cells through control of invadopodia stability. Oncogene 2014; 34: 4531-4544.
53. Jaiswal M, Gremer L, Dvorsky R, Haeusler LC, Cirstea IC, Uhlenbrock K et al. Mechanistic insights into specificity, activity, and regulatory elements of the regulator of G-protein signaling (RGS)-containing Rho-specific guanine nucleotide exchange factors (GEFs) p115, PDZ-RhoGEF (PRG), and leukemia-associated RhoGEF (LARG). J Biol Chem 2011; 286: 18202-18212.
54. Chikumi H, Barac A, Behbahani B, Gao Y, Teramoto H, Zheng Y et al. Homo-and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential. Oncogene 2004; 23: 233-240.
55. Coffman L, Mooney C, Lim J, Bai S, Silva I, Gong Y et al. Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer Biol Ther 2013; 14: 184-192.
56. Kim SJ, Kim JS, Kim SW, Yun SJ, He J, Brantley E et al. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol 2012; 5: 39-47.
57. Kim SJ, Kim JS, Kim SW, Brantley E, Yun SJ, He J et al. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer. Neoplasia 2011; 13: 167-179.
58. Kim SJ, Lee HJ, Kim SW, Choi HJ, He J, Wu Q et al. Macitentan, a dual endothelin receptor antagonist, in combination with temozolomide leads to glioblastoma regression and long-term survival in mice. Clin Cancer Res 2015; e-pub ahead of print 23 June 2015; doi:10.1158/1078-0432.CCR-14-3195.